Anascorp

Scorpion Antivenoms and Immunoglobulins

Scorpion antivenin is administered intravenously by infusion.
Visually inspect parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit. Do not use if the solution is turbid.

Reconstitution:
Reconstitute each vial of scorpion antivenin with 5 ml of sterile normal saline.
Mix by swirling gently.
If using more than one vial, combine the contents of each vial promptly.
Further dilute dose to a total volume of 50 ml with sterile normal saline (0.9% NaCl injection).
Discard any partially used vials.
Intravenous infusion:
Infuse dose intravenously over 10 minutes.
Monitor patient closely during and up to 60 minutes following the infusion completion.

serum sickness / Delayed / 0.5-0.5
anaphylactoid reactions / Rapid / Incidence not known

ocular inflammation / Early / Incidence not known
hypoxia / Early / Incidence not known
ataxia / Delayed / Incidence not known
palpitations / Early / Incidence not known
lymphadenopathy / Delayed / Incidence not known

vomiting / Early / 4.7-4.7
fever / Early / 4.1-4.1
rash / Early / 2.7-2.7
nausea / Early / 2.1-2.1
pruritus / Rapid / 2.0-2.0
headache / Early / 1.9-1.9
rhinorrhea / Early / 1.8-1.8
myalgia / Early / 1.6-1.6
fatigue / Early / 1.6-1.6
cough / Delayed / 1.4-1.4
diarrhea / Early / 1.3-1.3
lethargy / Early / 1.1-1.1

Anascorp

Rx

Polyvalent antivenin useful against scorpion stings.
First specific treatment to neutralize toxin from Centruroides scorpion stings, particularly Centruroides sculpturatus in the United States; children and infants are more likely than adults to have severe stings and resulting symptoms and hospitalization.
Derived from equine plasma; early and delayed hypersensitivity reactions are possible.

The initial dose is 3 vials of antivenin diluted to a total volume of 50 mL normal saline and administered IV over 10 minutes. Additional doses of 1 vial of antivenin diluted to a total volume of 50 mL normal saline and administered IV over 10 minutes may be given at 30- to 60-minute intervals as needed. Data from use in Mexico and Arizona, including data in critically ill children (age 6 months to 18 years) from a double-blind, placebo-controlled study , suggest that use of the antivenin in most patients can resolve significant clinical toxicity within about 4 hours after treatment.

Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.

Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.

There are no drug interactions associated with Scorpion Antivenin, Antivenin Centruroides sculpturatus Equine products.

Anascorp Intravenous Inj Pwd F/Sol

No maximum dosage information can be definitely assigned at this time.

No maximum dosage information can be definitely assigned at this time.

No maximum dosage information can be definitely assigned at this time.

No maximum dosage information can be definitely assigned at this time.

No maximum dosage information can be definitely assigned at this time.

No maximum dosage information can be definitely assigned at this time.

The clinical consequences of scorpion envenomation are the result of ion channel specific toxins present in the venom which stimulate action potentials throughout the peripheral nervous system. Scorpion antivenin is composed of venom specific F(ab')2 fragments of immunoglobulin G. These fragments bind and neutralize the toxins allowing for redistribution away from target tissues and elimination from the body.

Scorpion antivenin is administered intravenously. In clinical trials, 95—100% of patients responded to scorpion antivenin with relief of systemic symptoms in less than four hours after initiating treatment. Scorpion antivenin is standardized for potency in mice in terms of its LD50 neutralizing capacity per mL. Based on this assay system, the reconstituted contents of each vial (5 mL) will neutralize approximately 150 LD50 of Centruroides scorpion venom and contains no more than 120 mg of protein. In a pharmacokinetic study, 47.5 mg of scorpion antivenin was administered to eight healthy adult volunteers and blood samples were collected over 21 days. The following pharmacokinetic parameters were reported (mean +/- standard deviation): area under the curve (AUC) 706 +/- 352 mcg/ml x hr, clearance 83.5 +/- 38.4 ml/hr, half-life 159 +/- 57 hrs, and volume of distribution at steady-state 13.6 +/- 5.4 L.

It is not known whether scorpion antivenin causes fetal harm when administered during human pregnancy and animal reproduction studies have not been conducted. Scorpion antivenin should only be administered to a pregnant woman if the benefit clearly outweighs the risk.

It is not known whether scorpion antivenin is excreted in breast milk; caution should be used when administering to a breast-feeding woman. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, health care providers are encouraged to report the adverse effect to the FDA.